Clean Science and Technology reported a 10.5% year-on-year revenue rise to ₹2.7 billion for Q1 FY27. The growth was supported by higher product prices and strong demand in its HALS segment. Investors should track the execution of new supply agreements with Kemin Industries and Geneus, which aim to contribute to future revenue.
Clean Science and Technology reported revenue of ₹2.7 billion for the first quarter ending June 2026, reflecting a 10.5% growth compared to the same period last year. On a quarter-on-quarter basis, revenue increased by 7.7%. The performance was supported by the company’s Hindered Amine Light Stabilizers, or HALS, product line, which saw volumes reach approximately 1,000 tonnes during the quarter.
HALS Segment and Product Mix
A key factor in the company’s recent performance is the focus on higher-grade HALS products. This shift toward higher-value offerings helped improve average realisations to ₹550 per kilogram, rising from ₹440 per kilogram in the previous period. Exports have become an important part of this segment, currently accounting for 50% of HALS sales. Management has provided an outlook for the HALS business, projecting revenue between ₹2.5 billion and ₹3.0 billion, though actual results will depend on sustained demand and pricing stability in competitive international markets.
Strategic Partnerships and Future Growth
The company is looking to expand its business through long-term supply agreements. It recently announced a collaboration with Geneus, which the company expects to generate ₹3.0 billion to ₹3.5 billion in revenue over the next four years. Additionally, a five-year supply agreement has been signed with Kemin Industries. Investors should note that while these agreements provide a roadmap for future sales, the company has yet to disclose specific details regarding the capital spending required to support these projects. Monitoring the timeline and funding of this expansion will be important for assessing the company’s future cash flow and debt position.
Investor Context and Valuation
Clean Science currently trades at approximately 22 times its estimated earnings per share for the fiscal year 2028. Chemical companies often face pressure from fluctuating raw material costs and global pricing trends, which can impact profit margins. Unlike some peers in the specialty chemicals sector that may carry higher debt, Clean Science’s ability to maintain its margin profile while scaling up new segments remains a primary monitorable. The brokerage firm Prabhudas Lilladher has maintained a neutral stance on the stock, setting a price target of ₹745 based on their FY28 earnings projections. Future updates on the execution of the new supply agreements and the nature of the upcoming capital expenditure will be key factors for investors to follow in the coming quarters.